STOCKS TELEGRAPH

Tag: GRTS stock

  • Gritstone Bio Inc. (GRTS) Stock Shows Both Hope and Risk

    For an investor, a wise move would be to take a look at the speculative life science company Gritstone bio, Inc. (NASDAQ: GRTS). The present timing for this biotech stock is spectacular, considering it has demonstrated, through recently published preliminary clinical data, and critical milestone updates. Moreover, the stock is trading cheap at 80% below its price at the start of 2022.

    Positive Trial Updates by Gritstone

    Results from the phase 1/2 research by Gritstone Bio (GRTS) focusing on the effectiveness of SLATE vaccines, turned out to be highly promising. These vaccines saw testing for the treatment of patients with KRAS mutant MSS-CRC and NSCLC. The molecular response of the candidate was 39%, which led to an overall doubling of survival rate among KRAS mutant NSCLC patients. These results confirmed findings of earlier research which affirmed this association between the candidate and treatment, through checkpoint inhibitors and another trial employing GRANITE.

    Biotech technicalities aside, Gritstone is doing extremely well in developing its promising SLATE vaccine, which could be a game changer in the treatment of solid tumors and result in a value explosion.

    The Major GRTS Risk

    Before investing in this biotech, investors should be aware of an inherent risk that links to a critical Gritstone program, which is vital to the company’s financial sustainability. The continuing CORAL program, which is under investigation in three ongoing phases 1 trials, would be the main danger to take into account in the near future. All of these studies’ findings are anticipated to be released in the upcoming months. Although shareholders are hoping that the CORAL program successfully progresses, there is no assurance that the effectiveness of the candidate will be sufficient to justify future research. Because the market at present shows over-saturation of available Covid-19 vaccines and therapies available, it is probable that these trials will halt if the trials do not ensure the required efficacy.

    Conclusion

    GRTS has essentially been a high-risk high-return play that could spell a breakthrough if successful. Its recent milestone achievements are significant in establishing efficacy, yet its risks remain a point of concern for investors.

  • COVID-19 Vaccine 1st Cohort Positive Clinical Results: Gritstone Bio Inc. (GRTS) Bullish Premarket

    On January 04, Gritstone Bio Inc. (GRTS) shared positive clinical data from the first cohort of the Phase 1 study of its Covid-19 vaccine. Consequently, the stock was trading at $7.53 apiece premarket at the last check on Wednesday.

    In the previous market session, the stock saw a huge loss of 42.41% at its close of $7.02. Following the announcement, the stock gained 7.26% in the premarket at the time of writing.

    The clinical-stage biotechnology company, Gritstone Bio Inc. has a market capitalization of $828.77 million. Currently, the company has 67.99 million shares outstanding in the market.

    GRTS’s CORAL Study

    The company’s CORAL program is designed to develop a second-generation COVID-19 vaccine. Moreover, the vaccine is being developed on the recognition of T cell immunity’s importance in protection against current and future Spike variants. In addition to robust neutralizing antibodies, the vaccine will also induce broad CD8+ T cell immunity.

    CORAL-BOOST is GRTS’s one of four trails in the CORAL program. It is studying the safety, reactogenicity, and immunogenicity of samRNA vaccine against SARS-CoV-2. Further, the vaccine is being studied as a booster in adults under 60 (after two doses of AstraZeneca’s Vaxzervria).

    On Tuesday, the company announced positive clinical data from the first cohort of the CORAL-BOOST study. As per the results, the vaccine demonstrated robust neutralizing antibody responses to Spike and strong CD8+ T cell responses. According to the co-founder, President, and CEO of GRTS, Andrew Allen, this validates the company’s infectious disease platform’s potential.

    Added to this, the vaccine also constructed a favorable safety profile and was well-tolerated. Given the positive data, the company has increased enrollment to 120 subjects and will also evaluate an additional second dose.

    Recent Announcements

    On December 30, the company announced its management’s presentations at three upcoming investors conferences in January. These are:

    1. JP Morgan 40th Annual Global Healthcare Conference on Thursday, January 13.
    2. C Wainwright BioConnect Conference 2022, on Monday, January 10.
    3. Riley Securities’ 2022 Virtual Oncology Conference, on January 27.

    Mr. Allen will be presenting at the above-mentioned conferences on the given dates.

    GRTS Q3 Financial Highlights

    On November 04, the company announced its financial results for the third quarter of 2021.

    The company had a collaboration revenue of $2.4 million in Q3 of 2021, against $0.8 million in the same period of 2020.

    Furthermore, GRTS ended the quarter with cash, cash equivalents, marketable securities, and restricted cash of $216.4 million.

  • Gritstone Oncology Inc. (GRTS) stock rises during after-hour trading. Let’s find out why?

    Gritstone Oncology Inc. (GRTS) stock rises during after-hour trading. Let’s find out why?

    Gritstone Oncology Inc. (GRTS) stock declined by 10.19% in the last trading closed while the GRTS stock rises by 11.35% during the after-hours trading session as Gritstone Oncology reported that the first individual has been medicated with its candidate COVID-19 vaccine in a Phase 1 trial as part of GRTS’s “CORAL” program. Gritstone Oncology, a clinical-stage biotechnology firm focuses on the development of immunotherapies to treat a variety of cancers and infectious diseases.

    What is happening?

    In a Phase 1 trial, the first person has been dosed under Gritstone’s “CORAL” program with its COVID-19 vaccine. The researchers are investigating the immunogenicity and protection of delivering SARS-CoV-2 viral antigens using their self-amplifying mRNA (SAM) and/or adenoviral vectors, which contain both Spike and other viral antigens not included in currently approved vaccines. The National Institute of Allergy and Infectious Diseases (NIAID) is funding the Phase 1 study, which is being carried out by their Infectious Diseases Clinical Research Consortium.

    In Phase 1 clinical trial which is a multicenter, open-label, dose- and age-escalation study in healthy adult participants to determine the immunogenicity and efficacy of Gritstone’s CORAL COVID-19 vaccine. In a parallel design, heterologous and homologous key vaccinations of the adenoviral vector and/or SAM vector representing SARS-CoV-2 Spike alone or Spike plus additional SARS-CoV-2 T cell epitopes are examined.

    Conclusion

    Gritstone through its CORAL program is expecting some visible results since it is considered as an efficient vaccine to counter the challenges faced by a coronavirus and also those which will possibly come out around novel Spike variants. Needless to say that COVID-19 is the most problematic thing that the world is going through for the past year and under such circumstances, GRTS bringing the efficient vaccine is definitely a remarkable achievement. Possibly due to this new positive development in Gritstone, the investors are making valuable investments in GRTS shares, Hence the GRTS stock price is rising in after-hours.